Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 2:2021:9965850.
doi: 10.1155/2021/9965850. eCollection 2021.

Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission

Affiliations

Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission

Mercedes García-Gasalla et al. Can J Infect Dis Med Microbiol. .

Abstract

Background: Early identification of COVID-19 patients at risk of critical illness is a challenging endeavor for clinicians. We aimed to establish immunological, virological, and routine laboratory markers, which, in combination with clinical information, may allow identifying such patients.

Methods: Blood tests to measure neutrophil/lymphocyte ratio (NLR) and levels of ferritin, CRP, D-dimer, complement components (C3 and C4), cytokines, and lymphocyte subsets, as well as SARS-Cov-2 RT-PCR tests, were performed in COVID-19-confirmed cases within 48 hours of admission. RT-PCR cycle threshold (Ct) values from oropharyngeal or nasopharyngeal swabs were determined on the day of admission. Symptom severity was categorized as mild (grade 1), severe (grade 2), or critical (grade 3).

Results: Of 120 patients who were included, 49 had mild, 32 severe, and 39 critical COVID-19. Levels of ferritin >370 ng/mL (OR 16.4, 95% CI 5.3-50.8), D-dimer >440 ng/mL (OR 5.45, 95% CI 2.36-12.61), CRP >7.65 mg/dL (OR 11.54, 95% CI 4.3-30.8), NLR >3.77 (OR 13.4, 95% CI 4.3-41.1), IL-6 >142.5 pg/mL (OR 8.76, 95% CI 3.56-21.54), IL-10 >10.8 pg/mL (OR 16.45, 95% CI 5.32-50.81), sIL-2rα (sCD25) >804.5 pg/mL (OR 14.06, 95% CI 4.56-43.28), IL-1Ra >88.4 pg/mL (OR 4.54, 95% CI 2.03-10.17), and IL-18 >144 pg/mL (OR 17.85, 95% CI 6.54-48.78) were associated with critical COVID-19 in the univariate age-adjusted analysis. This association was confirmed in the multivariate age-adjusted analysis only for ferritin, CRP, NLR, IL-10, sIL-2rα, and IL-18. T, B, and NK cells were significantly decreased in critical patients. SARS-CoV-2 was not detected in blood except in 3 patients who had indeterminate results. RT-PCR Ct values from oropharyngeal or nasopharyngeal swabs on admission were not related to symptom severity.

Conclusion: Ferritin, D-dimer, CRP, NLR, cytokine (IL-18 and IL-10), and cytokine receptor (IL-6, IL1-Ra, and sCD25) test results combined with clinical data can contribute to the early identification of critical COVID-19 patients.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Performances of ROC curves in predicting critical patients for ferritin, CRP, NLR, IL-10, sCD25 (sIL-2rα), and IL-18. The univariate and multivariate logistic regression analysis distinguished critical from mild and severe disease patients. Abbreviations: CRP, C-reactive protein; NLR, neutrophil/lymphocyte ratio; and s CD25s (sIL-2rα), serum IL2 receptor alpha.

References

    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. 2020;8(2):113–122. doi: 10.46234/ccdcw2020.032. - DOI - PMC - PubMed
    1. Li Q., Guan X., Wu P., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine. 2020;382(13):1199–1207. doi: 10.1056/nejmoa2001316. - DOI - PMC - PubMed
    1. Coronavirus Disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update.
    1. Cen Y., Chen X., Shen Y., et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study. Clinical Microbiology and Infection. 2020;26(9):1242–1247. doi: 10.1016/j.cmi.2020.05.041. - DOI - PMC - PubMed
    1. Salto-Alejandre S., Roca-Oporto C., Martín-Gutiérrez G., et al. A quick prediction tool for unfavourable outcome in COVID-19 inpatients: development and internal validation. Journal of Infection. 2020;82(2):e11–e15. doi: 10.1016/j.jinf.2020.09.023. - DOI - PMC - PubMed